Focused Wealth Management’s Co-Diagnostics CODX Stock Holding History

Focused Wealth Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3	Closed	-$1K	–	943
2022 Q1	$1K	Buy	+3	New	+$621	﹤0.01%	859

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Focused Wealth Management's CODX Position: Q2 2022 in Review

Focused Wealth Management sold out of Co-Diagnostics (CODX) in Q2 2022, closing a stake of 3 shares — an estimated $1K sold.

Focused Wealth Management first reported a position in CODX in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 69 funds tracked by Wall St. Rank hold CODX as of Q2 2022.

Focused Wealth Management reported no remaining Co-Diagnostics position as of Q2 2022 after selling out during the quarter.
Focused Wealth Management sold 3 Co-Diagnostics shares in Q2 2022, an estimated $1K.
Focused Wealth Management first reported a position in Co-Diagnostics in Q1 2022 and held it in 1 quarter.
Focused Wealth Management's Co-Diagnostics position peaked at $1K in Q1 2022.
69 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2022.

Based on Focused Wealth Management's 13F filing for Q2 2022, filed 4 Aug 2022.